

## **REMARKS**

Reconsideration and withdrawal of the rejections of the claimed invention is respectfully requested in view of the amendments, remarks and enclosures herewith, which place the application in condition for allowance.

### **I. STATUS OF CLAIMS AND FORMAL MATTERS**

Claims 1-14 are still pending in this application. No new matter has been added by this amendment.

It is submitted that the claims, herewith and as originally presented, are patentably distinct over the prior art cited in the Office Action, and that these claims were in full compliance with the requirements of 35 U.S.C. § 112.

### **II. THE 35 U.S.C. 103(a) REJECTION HAS BEEN OVERCOME**

Claims 1-14 were rejected as allegedly being obvious by Nara et al. (US 6,245,351 - "Nara") in view of Rupprecht et al. (DE 101 46 251 - "Rupprecht"). The applicants request reconsideration of this rejection for the following reasons.

#### **Background**

Although the rejection has been modified to a combination of Nara and Rupprecht, the rejection is similar to the previous rejection of Nara in combination with Horstmann previously presented.

As such, the applicants will first rebut the "Response to Arguments" section on page 2 of the Office Action. Should this response be deemed not to overcome the rejection by itself, the applicants request consideration of their rebuttal in combination with their revised arguments against the combination of Nara and Rupprecht which follows afterwards.

#### **Rebuttal to "Response to Arguments" section on page 2 of Office Action**

While the Examiner is certainly not limited to reciting case law from Appendix II (List of Decisions Cited) of the MPEP, the applicants note that *In re Stover*, 146 F.2d 299, 56 USPQ 525 (CCPA 1944) is not among the decisions cited in Appendix II.<sup>1</sup>

Furthermore, MPEP 2144.04 states in part that "...if the facts in a prior legal decision are sufficiently similar to those in an application under examination, the examiner may use the rationale used by the court."

*Stover* was relied upon for the proposition that "...it is a matter of choice and not inventions (sic) to select any particular shape desired in the finished product." (see last three lines on page 2 of the Office Action). The applicants note that case law with regard to design changes, shapes and sizes are often in the context of the mechanical arts or related to devices and *Stover* is no different.

The claims in *Stover* related to an elongated paper container particularly adapted for receiving and packaging ice cream, or other plastic foodstuffs, for subsequent sale to the public in sanitary and predetermined units. *Id.* @ 300.

The Board in *Stover* "...decide that it would not amount to invention to provide the container of Clearwater with the markings as taught by Tiffany, and with the vents or openings for the escape of air as taught by Ortner or Massey, and that no patentable conception is involved in filling a container through the urge of gravity, as that procedure is but a common expedient for filling containers with a liquid or semiliquid substance. The rejected claims herein cover an article, the construction of which, in view of the prior art, would be within the obvious and expected routine skill of those laboring in the art, and are, therefore, unpatentable." *Id.* @ 301-302.

Regardless of whether the decision in *Stover* would have withstood the scrutiny of the standards for obviousness set forth in 35 U.S.C. 103 introduced eight years later in the Patent Act of 1952, the facts of *Stover* do not resemble the facts of the presently claimed application.

Unlike the design choice for a mechanical device in *Stover*, the Examiner here is attempting to provide an equivalency for all forms of pharmaceutical dosage forms which would be unrecognizable to those of ordinary skill in the pharmaceutical arts.

Whole industries have been built on selecting and developing a specific form of drug delivery methods and as such one of ordinary skill in the art concerned with the formation of enteric capsules as in Nara would not use the teachings of Rupprecht (or any other film forming prior art) as this does not assist in the production of a completely different pharmaceutical dosage delivery form (i.e. capsule vs. film).<sup>2</sup>

---

<sup>1</sup> And also predates the Patent Act of 1952, i.e. prior to the establishment of 35 U.S.C. 103.

<sup>2</sup> By way of example, the applicants provide the table of contents from *Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems (Eighth Edition)*, Allen et al., Lippincott Williams & Wilkins (2005).

The differences in pharmaceutical dosage delivery forms is also recognized by the PTO's classification system, Class 424, subclass 400 (Preparations Characterized by Special Physical Form), Class 424, subclass 451+ (Capsules), Class 424, subclass 484 (Matrices). The applicants do not suggest that prior art from differing classes can never be used in combination, but for the presently claimed invention, the modifications required to be made for the combination of Nara and Rupprecht would not be obvious to one of ordinary skill in the art as their respective pharmaceutical dosage forms are so vastly different; one of ordinary skill in the art would not be able to magically select a single element from one reference (or even look to the reference) for combination with the other reference to arrive at the applicants' claimed film form with regard to the product claims (claims 5-9 and 14) and certainly not for the process claims of making the film form (claims 1-4 and 10-13).

**Arguments against the combination of Nara and Rupprecht establishing a *prima facie* holding of obviousness**

The rejection of the pending claims shows the traps associated when prior art is apparently relied upon for their hits of selected keyword terms without considering the context of the reference or the applicants' claimed invention.

While the Office Action identified features of the applicants' invention and partially identified the differences between the claimed invention and the teachings of Nara, the applicants' claimed invention and the Nara and Rupprecht references did not appear to be considered as a whole as is required when making a determination of obviousness. *See MPEP 2141.02.*

First, the difference between Nara and the claimed invention is not limited merely to the step of drying the mixture or that the dosage is in film form for surface/topical administration (which are substantial differences in and of themselves), but also includes the additional differences that:

- (1) the hydrophilic polymers crosslinked with at least one polyacrylic acid derivative (and for the claims as amended, the hydrophilic polymers are crosslinked by the polyacrylic acid derivative *in situ*)<sup>3</sup>; and

---

<sup>3</sup> Moreover, there appeared to be a misunderstanding in the Office Action about the teaching within Nara about crosslinking. The liquid coating composition used by Nara comprises of a water-insoluble substance, swellable

(2) there is no mention of the simultaneous spraying of an aqueous solution of the hydrophilic polymers and aqueous solution of the polyacrylic acid derivative.

Nara also differs from the applicants' claimed invention in that their method for producing their unrelated composition does so in a manner which teaches away from either Rupprecht or the applicants' claimed process. Nara prepares a drug-containing core following by spray-coating the resulting core with a liquid coating composition; for illustrative purposes see Example 3 (col. 9, lines 8-13) and Example 7 (col. 10, lines 43-48) – "These core granules were placed in a spiral flow type coating machine and spray coated with hydroxypropylmethylcellulose dissolved in a mixture of ethanol and water...to yield coated granules."

What Nara is teaching is an active agent in an inner core which is an element not taught in Rupprecht or in the applicants' claimed invention and Nara does not suggest the active agent being in anything which would be considered equivalent to a film.

As Rupprecht does not address these differences, the combination of Nara and Rupprecht do not render the applicants' claims for this reason alone as all claim elements are not taught or suggested by the combination of Nara and Rupprecht. Moreover, in the context of Nara's invention, it would be nonsensical to place the active ingredient in a film which coats Nara's inner core as this film is destroyed in providing the enteric effect in allowing the composition to pass through the stomach acidic environment and would only serve to waste valuable active ingredient.

In addition, even if Rupprecht had taught all the missing elements, when considering Nara as a whole, it is not even related to the type of dosage forms which is taught both by the applicants' claimed invention and by Rupprecht (i.e. film forms). Nara refers to an alternative form of an *enteric* capsule consisting of a drug core with an outer coating which is clearly identified in the "Summary of the Invention" (see col. 1, lines 50-57 – "...to develop a controlled-release composition for *oral administration* coated with a coating composition which is capable of releasing drug at higher rates in the *intestinal tract* than in the stomach to maintain an almost constant plasma concentration of drug and ensure effect of drug in the body for an extended period of time.")

---

polymer and an *already crosslinked polymer*, i.e. the swellable polymer is *not crosslinked* to the crosslinked polymer.

In contrast, Rupprecht is directed to a device for making films and only generically refers to the film making process which is completely different than the controlled-release compositions of Nara. Even if one of ordinary skill in the art were permitted to pick and choose elements from the combination of Nara and Rupprecht at will, the skilled artisan still would not achieve the applicants' claimed process steps of claims 1-4 and 10-13, nor would they obtain the products formed by the process.

Moreover, one of ordinary skill in the art would not look to use Rupprechts' device to make modifications to the invention of Nara, given the differences in forms, as there is no expectation of success that taking an isolated element from Rupprecht could be incorporated into the controlled-release composition of Nara while maintaining the intended use of Nara, i.e. releasing drug at higher rates in the *intestinal tract* than in the stomach to maintain an almost constant plasma concentration of drug.

Therefore, it would not have been obvious to combine Rupprecht with Nara as there was no reason to combine teachings from disparate inventions nor was there a reasonable expectation of success for the combination proffered in the Office Action.

**CONCLUSION**

In view of the remarks and amendments herewith, the application is believed to be in condition for allowance. Favorable reconsideration of the application and prompt issuance of a Notice of Allowance are earnestly solicited. The undersigned looks forward to hearing favorably from the Examiner at an early date, and, the Examiner is invited to telephonically contact the undersigned to advance prosecution. The Commission is authorized to charge any fee occasioned by this paper, or credit any overpayment of such fees, to Deposit Account No. 50-0320.

Respectfully submitted,  
FROMMER LAWRENCE & HAUG LLP

By: /Howard C. Lee/  
Marilyn M. Brogan     Howard C. Lee  
Reg. No. 31,223     Reg. No. 48,104  
Telephone:     (212) 588-0800  
Facsimile:     (212) 588-0500

# **Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems**

E I G H T H   E D I T I O N



**Loyd V. Allen, Jr.**  
**Nicholas G. Popovich**  
**Howard C. Ansel**



LIPPINCOTT WILLIAMS & WILKINS

Senior Acquisitions Editor: David B. Troy  
Senior Managing Editor: Matthew J. Hauber  
Marketing Manager: Christen DeMarco  
Production Editor: Jennifer Ajello  
Designer: Doug Smock  
Compositor: Peirce Graphic Services, LLC.  
Printer: Courier—Kendallville

Copyright © 2005 Lippincott Williams & Wilkins

351 West Camden Street  
Baltimore, MD 21201

530 Walnut Street  
Philadelphia, PA 19106

All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner.

The publisher is not responsible (as a matter of product liability, negligence, or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care that should not be construed as specific instructions for individual patients. Manufacturers' product information and package inserts should be reviewed for current information, including contraindications, dosages, and precautions.

*Printed in the United States of America*

#### Library of Congress Cataloging-in-Publication Data

Allen, Loyd V.

Ansel's pharmaceutical dosage forms and drug delivery systems / Loyd V. Allen Jr., Nicholas G. Popovich, Howard C. Ansel.—8th ed.  
p. ; cm.

Rev. Ed. of: *Pharmaceutical dosage forms and drug delivery systems* / Howard C. Ansel, Loyd V. Allen, Jr., Nicholas G. Popovich. 7th ed. c1999.

Includes bibliographical references and index.

ISBN 0-7817-4612-4

1. Drugs—Dosage forms. 2. Drug delivery systems. I. Title: *Pharmaceutical dosage forms and drug delivery systems*. II. Popovich, Nicholas G. III. Ansel, Howard C., 1933– IV. Ansel, Howard C., 1933– *Pharmaceutical dosage forms and drug delivery systems*. V. Title.

[DNLM: 1. Dosage Forms. 2. Drug Delivery Systems. QV 785 A427a2004]

RS200.A57 2004

615'.1—dc22

2004048276

*The publishers have made every effort to trace the copyright holders for borrowed material. If they have inadvertently overlooked any, they will be pleased to make the necessary arrangements at the first opportunity.*

To purchase additional copies of this book, call our customer service department at (800) 638-3030 or fax orders to (301) 824-7390. International customers should call (301) 714-2324.

Visit *Lippincott Williams & Wilkins on the Internet*: <http://www.LWW.com>. Lippincott Williams & Wilkins customer service representatives are available from 8:30 am to 6:00 pm, EST.

05 06 07 08 09  
3 4 5 6 7 8 9 10



# Contents

Preface .....	v
Acknowledgments .....	vii
List of Physical Pharmacy Capsules .....	xi
<b>Section I. Introduction To Drugs, Drug Dosage Forms, and Drug Delivery Systems</b>	
1 Introduction to Drugs and Pharmacy .....	1
2 New Drug Development and Approval Process .....	25
3 Current Good Manufacturing Practices and Current Good Compounding Practices .....	67
<b>Section II. Drug Dosage Form and Drug Delivery System Design</b>	
4 Dosage Form Design: Pharmaceutical and Formulation Considerations .....	92
5 Dosage Form Design: Biopharmaceutical and Pharmacokinetic Considerations .....	142
<b>Section III. Solid Dosage Forms And Solid Modified-Release Drug Delivery Systems</b>	
6 Powders and Granules .....	186
7 Capsules .....	204
8 Tablets .....	227
9 Solid Oral Modified-Release Dosage Forms and Drug Delivery Systems .....	260
<b>Section IV. Semisolid Dosage Forms and Transdermal Systems</b>	
10 Ointments, Creams, and Gels .....	276
11 Transdermal Drug Delivery Systems .....	298
<b>Section V. Pharmaceutical Inserts</b>	
12 Suppositories and Inserts .....	316
<b>Section VI. Liquid Dosage Forms</b>	
13 Solutions .....	336
14 Disperse Systems .....	385
<b>Section VII. Sterile Dosage Forms and Delivery Systems</b>	
15 Parenterals .....	443
16 Biologics .....	506
17 Special Solutions and Suspensions .....	540
<b>Section VIII. Novel and Advanced Dosage Forms, Delivery Systems, and Devices</b>	
18 Radiopharmaceuticals .....	570
19 Products of Biotechnology .....	600
20 Novel Dosage Forms and Drug Delivery Technologies .....	652